Special AT-rich sequence-binding protein 2 (SATB2) expression in colorectal carcinoma; a possible future perspective for targeted therapy
Immunopathologia Persa, ISSN: 2423-8015, Vol: 5, Issue: 2, Page: e13-e13
2019
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Review Description
The use of SATB2 (special AT rich sequence binding protein2), immunohistochemical expression in colorectal carcinoma has a well-known value as a sensitive and specific diagnostic marker. Researches in literature are still being done to explore whether it has a prognostic value. The aim of this editorial is to include our insights from the most recently published researches highlighting the role of SATB2 as a cancer stem cell marker for colorectal carcinoma which would open a new scope for trials and researches on SATB2 targeted therapy.
Bibliographic Details
Maad Rayan Publishing Company
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know